Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis
P/E 29.52×· 5Y range 11.18–59.13×· 65th percentile of history
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy7 analystsStrengths
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓ROE 19.0% — efficient capital deployment
Risks
- ⚠Altman Z 0.6 — distress-zone balance sheet
- ⚠7 loss-making years in recent history
- ⚠Interest coverage 2.4× — thin debt cushion
What's happening with TEVA
Price History
5-Year Weekly Candlestick Chart
Profile
Strong growth; valuation lags behind.
How is each axis scored?
- Valuation42/100 · Weak
- P/E vs own history (65th pct)5/25
- FCF yield (2.6%)5/25
- P/S (2.6x)20/25
- EV/EBIT (19.5x)12/25
- Growth81/100 · Strong
- Revenue CAGR (2.1%)6/25
- Net income CAGR (35.6%)25/25
- EPS CAGR 5Y (33.9%)25/25
- Fwd implied growth (106.3%)25/25
- Profitability70/100 · Moderate
- ROIC (25.5%)25/25
- ROE (19.0%)20/25
- Net margin (9.0%)13/25
- Operating margin (13.2%)12/25
- Financial Health50/100 · Moderate
- Altman Z (0.56)3/25
- Current ratio (1.01)12/25
- Interest coverage (2.4x)10/25
- Net cash / debt (Net cash)25/25
- Quality63/100 · Moderate
- Piotroski F (7/9)22/25
- Beneish M (-2.40)20/25
- FCF conversion (75%)15/25
- Margin stability (σ 18.7%)6/25
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Show more
Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Headquarters: TEL AVIV · Employees: 32,842 · Website ↗
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
Valuation
42D+P/E (TTM)29.5xC
Grade C: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 11.2x–59.1x · 65th pct
P/FCF29.6xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield2.6%C
Grade C: LowTTM FCF / Market Cap — vs own 5Y history: -1.3%–14.0% · 20th pct
P/S (TTM)2.63xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 0.5x–2.7x · highest in history
EV/EBIT19.5xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 3.6x–92.1x · 50th pct
EV/Sales3.4xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E14.3xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio5.56xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
70B+ROIC25.5%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE19.0%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA1.8%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin9.0%C
Grade C: AverageNet Income / Revenue
Operating Margin13.2%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin52.1%A
Grade A: PremiumGross Profit / Revenue
FCF Margin6.8%D
Grade D: LowFCF / Revenue
True FCF Margin5.8%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
81ARevenue CAGR2.1%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR35.6%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)33.9%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth106.3%A
Grade A: HighImplied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)+6.5%C
Grade C: DilutiveShare count change over 5Y
SBC / Net Income10.6%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.0%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
50CAltman Z-Score0.56D
Grade D: DistressBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.01xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.72xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage2.4xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.32xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt1.43xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
63BPiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.40A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion74.9%C
Grade C: AverageFCF / Net Income
Margin Stability18.7%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue3.1%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.42xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)$1.33
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$3.09
Cash & short-term investments per share (Finnhub)
Book Value / Share$6.88
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$2.61B
Total debt obligations (short + long term)
Cash & Equiv.$3.74B
Cash and short-term investments
Net Debt$-1.13BA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$8.23B
Shareholders' equity (book value)
Asset / Liability1.26xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$45.71B
Current Market Capitalization
Beta0.42B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
Company is effectively debt-free after netting cash. · Current P/E of 29.5x sits at the 65th percentile of its historical range.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 27, 2026
Key Insights: Teva Pharmaceutical Industries Limited (TEVA)
TEVA is down 2.56% at the last close. Teva Pharmaceutical Industries Limited meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 0.56 is below the 1.81 distress threshold — an elevated financial-risk flag.
- Beneish M-Score of -2.40 suggests a low likelihood of earnings manipulation.
- Company is effectively debt-free after netting cash.
- Teva Pharmaceutical Industries Limited posted a net loss in 7 of 9 available completed fiscal years (2017–2025).
Insider Transactions
Recent SEC Form 4 filings · 8 records
| Transaction date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Savage Brian Filed | Savage Brian | SellOption exercise | -4503 | |
Savage Brian Filed | Savage Brian | SellOpen market sale | -314 | |
Savage Brian Filed | Savage Brian | SellOpen market sale | -2525 | |
Savage Brian Filed | Savage Brian | SellOpen market sale | -4503 | |
Savage Brian Filed | Savage Brian | BuyOption exercise | +4.5K |
Show 3 more filingsShow fewer filings
| Transaction date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
MIGNONE ROBERTO Filed | MIGNONE ROBERTO | SellOpen market sale | -367600 | |
Weiss Amir Filed | Weiss Amir | SellOption exercise | -2500 | |
Weiss Amir Filed | Weiss Amir | SellOpen market sale | -2500 |
See how TEVA ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all TEVA moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 21 | Regular | 40.50 | +3.90% | 2.60 |
Frequently Asked Questions about TEVA
What is the current Teva Pharmaceutical Industries Limited (TEVA) stock price?
TEVA is trading at $39.19 at the last market close, down 2.56% on the session. PreMarketPrice tracks TEVA pre-market, intraday and after-hours prices.
Is TEVA stock a buy right now?
PreMarketPrice's quantitative model rates Teva Pharmaceutical Industries Limited's financial health at 50/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is TEVA stock overvalued?
Teva Pharmaceutical Industries Limited trades at a trailing P/E of 29.5 and our valuation score rates it 42/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Teva Pharmaceutical Industries Limited report earnings?
No confirmed earnings date is currently scheduled for TEVA. The Earnings section lists recent reports and updates as dates are announced.
What sector does Teva Pharmaceutical Industries Limited operate in?
Teva Pharmaceutical Industries Limited operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Teva Pharmaceutical Industries Limited do?
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer.
About Teva Pharmaceutical Industries Limited (TEVA) Stock
Teva Pharmaceutical Industries Limited (TEVA) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Teva Pharmaceutical Industries Limited is trading at $39.19, down 2.56% on the day with a market capitalization of $45.7 billion. The financial health score for TEVA is 50/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for TEVA stock.
TEVA Stock Analysis & Key Metrics
On PreMarketPrice, you can track Teva Pharmaceutical Industries Limited (TEVA) across multiple dimensions:
- Pre-market price & movement: Real-time TEVA stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for TEVA with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Teva Pharmaceutical Industries Limited across multiple reporting periods.
- Financial health score: A composite score of 50/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for TEVA.
- Sector peers: Compare TEVA against 10 other healthcare stocks on key financial metrics.
Is TEVA a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Teva Pharmaceutical Industries Limited (TEVA) as an investment. The financial health score of 50/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Teva Pharmaceutical Industries Limited (TEVA) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.